🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧐Do you have a patient with de novo #metastaticbreastcancer and want to have an idea of prognosis? 👀Check out 👀 our free online calculator based on Journal of Clinical Oncology article (ascopubs.org/doi/10.1200/JC…)!! 👇👇👇👇 mbc.ocsresearch.com/#/Calculator

#SABC24 Educational Session 1 : Mind the Gap — Breast Cancer in the Young ▶️ About Ovarian Suppression OncoAlert #OncoAlertAF

Ada Waks presents the long awaited Margot trial. Margetuximab vs Trastuzumab. No sign diff in pCR but numeric difference in HR+ in metabolic variants. #SABCS24 OncoAlert

Check out the Society's new video tutorials on assessing breast cancer risk. Visit breastsurgeons.org/news/?id=121 for more information. #asbrs Jennifer Plichta MD (she/her) Judy Boughey

Excellent present by ⁦Matteo Lambertini, MD PhD⁩ on risk reduction surgery in BRCA carriers ( under the age of 40 with a diagnosis of #breastcancer ⁦SABCS⁩ improvement in survival ⁦OncoAlert⁩ #sabcs24

WATCH: Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer. Azka Ali, MD Cleveland Clinic SABCS #SABCS24 #bcsm #oncology onclive.com/view/dr-ali-on…

At #SABCS24 GS2 EBCTCG analysis on overweight/obesity and prognosis in a large cohort of early breast cancer patients ➡️Continuous association of BMI with distant recurrence rate OncoAlert

🎙EUROPA Trial: ☢️ shows ⬆️ HRQOL and ⬇️⬇️ side effects vs. endocrine therapy in women 70+ with early-stage breast cancer❗️ OncoAlert 🎯 Objective: •☢️✖️ET as single-modality treatments for women aged ≥70 w/ luminal A-like breast cancer 🧪 Methods: •Design: Non-inferiority,

COMET Trial 2 year results:👱🏼‍♀️👩🏽‍🦳👩🏻 >40 w/ #DCIS w/ screen-detected, NG 1 or 2 ER and/or PR+ disease w/o evidence of invasive #breastcancer who underwent active monitoring had noninferior rate of invasive cancer compared to standard of care (surgery +/- ☢️)

A patient recently asked me what my best advice was for women as they age and the top two by far are: Vaginal estrogen cream and weightlifting.

Update: ✅ 5 of the highly awaited BC trials with positive results ❌ one negative trial (but with positive OS) Results from the remaining trials expected in 2025. Breast oncology keeps moving extremely fast.

Impact of breast cancer therapies on fertility! link.springer.com/article/10.100… excellent review by Jasmin Hundal, M.D., DipABLM, M.S., M.P.H. CCF Hematology Oncology Fellows Cleveland Clinic IM Cleveland Clinic MD Cleveland Clinic Hem-Onc Fellows Network OncoAlert Halle Moore, MD

Patients treated with AI + OFS had a higher risk of CVD than patients treated with tamoxifen (HR 2.20 (95% CI, 1.57 to 3.09)) but the absolute incidence rate difference was low

February Issue: Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative #BreastCancer Ayat ElSherif Anna Chichura, MD Dr Lauren Kopicky rdcu.be/eaFVi Eduard-Alexandru Bonci Syed A. Ahmad

Eliminating breast surgery for invasive breast cancer after neoadjuvent chemotherapy 👇🏼👇🏼👇🏼 No recurrence at 5 yr FU. ⁦Henry Kuerer⁩ #SSO2025 ⁦Society of Surgical Oncology⁩ ⁦MD Anderson Cancer Center⁩

For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. ja.ma/426mLaK Henry Kuerer HelenMJohnsonMD Simona F. Shaitelman MD, EdM

Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and may effectively induce regression in high-risk ductal carcinoma in situ (DCIS). ja.ma/41MjsGK

Outside of the POSITIVE trial, after stopping adjuvant endocrine therapy for pregnancy less than half of women resumed ET postpartum and they were twice as likely to recur as compared to women in the POSITIVE trial

#AudioVisualAbstract : Current State of Evidence-Based Long-Term Monitoring Protocols for Breast Plastic Surgery Patients isabel 👩🏻‍⚕️ M4 Anna Chichura, MD Holly Pederson MD rdcu.be/elSbS Syed A. Ahmad

A randomized trial of supplemental imaging for dense breast tissue showed that CEM and abbreviated MRI detected 3x as many invasive cancers as ABUS, with no significant difference in detection rate between CEM and MRI. Cancers found on CEM and MRI were 1/2 the size of those found